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Abstract 
Summary: Cardiovascular diseases are one of the main causes of death in the developed world, and represent the 
first cause of mortality in Spain. In addition to their associated morbidity, such disorders are important due to the 
number of affected individuals and the many patients subjected to treatment because of them. 
Objective: An update is provided on the oral manifestations seen in patients with arterial hypertension, ischemic 
heart disease, arrhythmias and heart failure, and on the dental management of such patients. 
Material and methods: A Medline-PubMed search was conducted of the literature over the last 10 years using the 
keywords: “cardiopathy”, “dental management”, “endocarditis”, “hypertension” and “arrhythmia”. A total of 31 
articles were reviewed, of which 22 were literature reviews, three were expert committee guides, four clinical trials 
and two case series. 
Results: The drug treatments used by these patients can give rise to oral manifestations in the form of xerostomia, 
lichenoid reactions, burning mouth sensation, loss of taste sensation, gingival hyperplasia and bleeding, as well as 
extraoral manifestations such as sialadenosis. An inadequately controlled cardiological patient constitutes a risk 
case in dental practice; dental surgeons therefore must take a series of aspects into account before treating such 
patients, in order to avoid complications.
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Introduction
Cardiovascular diseases are one of the main causes of 
mortality in the developed world (1). The two cardio-
vascular conditions that cause most deaths are ischemic 
heart disease and cerebrovascular disease, with heart fa-
ilure in third place.
In addition to their associated morbidity, such disorders 
are important due to the number of affected individuals 
and the many patients subjected to treatment because 
of them. Patients with cardiovascular disease constitute 
risk cases in dental practice, particularly in the absen-
ce of adequate medical control. It is therefore important 
for dental surgeons to know the medical problems of 
each individual patient, the treatments received, and the 
possibilities for dental treatment (2). In addition, dental 
surgeons must be able to identify medical emergencies 
and adopt the opportune measures to avoid them or treat 
them quickly and effectively.
The present study offers a review of the heart diseases 
most often seen in dental practice, such as arterial hyper-
tension, ischemic heart disease, arrhythmias and heart 
failure.
ARTERIAL HYPERTENSION 
Arterial hypertension (AHT) is an important health pro-
blem due to its high incidence and prevalence in the 
general population and the associated increase in risk 
of suffering cardiovascular disease in the form of chest 
pain (angina), myocardial infarction and cerebrovascu-
lar events (e.g., stroke) (3). Arterial hypertension affects 
6-8% of the general population and is the most common 
cardiovascular risk factor in Spain, with a prevalence of 
over 40% in patients over 35 years of age.
The blood pressure values considered to be normal were 
established by consensus as under 90 mmHg in the case 
of diastolic pressure, and under 140 mmHg in the case of 
systolic pressure (4). The latest revision of the guides for 
the evaluation and management of arterial hypertension 
of the National Committee on the Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC 
7) introduced the term “pre-hypertension” in reference to 
people with a systolic blood pressure of 120-139 mmHg 
or with a diastolic blood pressure of 80-89 mmHg (5) 
(Table 1). 
ISCHEMIC HEART DISEASE
Ischemic heart disease is the main cause of death in the 
developed world. In males and females, it represents the 
first cause of mortality over the age of 40 and 65 years, 
respectively (6). Mortality is maximum in the first hours 
after the triggering event, and approximately 50% of all 
affected individuals die before reaching hospital.
Ischemic heart disease is characterized by a reduction 
(partial or total) in coronary blood flow. In 90% of all 
cases (7), this occurs following thrombus formation se-
condary to an atheroma plaque that occludes the arte-
rial lumen, though other factors such as cold, physical 
exercise or stress can act as coadjuvant factors or (less 
frequently) trigger the event themselves. Chest pain (an-
gina) occurs when coronary occlusion is partial and no 
myocardial necrosis is produced, while acute myocar-
dial infarction is observed when coronary occlusion is 
total and necrosis is produced as a result. In turn, sudden 
death may also occur, generally as a result of arrhyth-
mias (6, 7).
- Acute myocardial infarction (AMI)
Acute myocardial infarction is characterized by acute, 
sudden onset and intense pain, of an oppressive natu-
re, located in the retrosternal or precordial region, and 
can irradiate to the arms, neck, back, jaw, palate or ton-
gue. The duration is over half an hour, and the pain does 
not subside with rest. The condition is accompanied 
by intense perspiration, nausea, vomiting, dyspnea and 
imminent death sensation, though it can also manifest 
as sudden loss of consciousness, mental confusion or 
weakness. The triggering stimuli are emotional stress, 
intense physical exercise or the existence of concomitant 
disease or surgery. So-called silent infarctions in turn are 
characterized by an absence of pain, and are more com-
mon in elderly individuals, in women and in diabetic 
patients (6, 7). 
The drugs used to treat AMI and administered for se-
condary prevention purposes comprise beta-blockers, 
calcium antagonists and the angiotensin-converting en-
zyme inhibitors (ACEIs) (7). 
- Chest pain (angina, angor pectoris)
Stable angina is preceded by physical exertion or emo-
tional stress (8), and consists of pain in the same loca-
CLASSIFICATION OF BLOOD PRESSURE IN ADULTS
Classification of blood pressure SBP (mmHg) DBP (mmHg)
Normal < 120 < 80
Prehypertension 120-139 80-89
 AHT
Stage 1 140-159 90-99
Stage 2 ≥ 160 ≥ 100
SBP: systolic blood pressure; DBP: diastolic blood pressure.
Table 1. Classification of blood pressure in subjects over 18 years of age (National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure)
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pril, lisinopril and quinapril) in turn can be associated to 
diuretics (furosemide) and vasodilators (isosorbide dini-
trate and hydralazine).
ENDOCARDITIS
Infectious endocarditis (IE) is an infrequent condition 
resulting from the association of morphological altera-
tions of the heart and bacteremia of different origins. It 
has been estimated that 14-20% of all cases of IE have a 
buccodental origin (12). Transient bacteremia is obser-
ved not only in dental treatments such as tooth extractions 
(51-85%) (13) or periodontal surgery (36-88%), but also 
during tooth brushing (26%) or when chewing gum (17-
51%). The mortality rate is 5-11% (13). Approximately 
50% of all cases of infectious endocarditis are caused by 
Streptococcus viridians (13-15). Infectious endocarditis 
is infrequent in young individuals, except intravenous 
drug abusers, which represent a high risk group (12). 
In these latter subjects, infectious endocarditis is a se-
rious problem, with an estimated incidence of 1.5-3.3 
per 1000 intravenous drug abusers (16), and an associa-
ted 5-10% mortality rate. These figures are decreasing, 
however, probably as a result of changing habits aimed 
at avoiding infection with the human immunodeficiency 
virus (HIV) (17). Recurrent infectious endocarditis is 
also commonly observed in these individuals (16).
Due to the important morbidity and mortality involved, 
antibiotic prophylaxis is considered necessary when 
planning dental treatment in individuals at risk (12), 
though according to Farbod et al. (15), daily activities 
such as tooth brushing twice a day for one year produ-
ces far greater bacteremia than that associated with tooth 
extraction. The percentage of patients with endocarditis 
who have received recent dental treatment varies greatly 
(3-40%), depending on the literature source (9). 
No studies have shown prophylaxis to be beneficial (14), 
and there is no evidence that prophylaxis with penicillin 
is effective (18). In this context, although there is no firm 
scientific evidence, the morbidity and mortality associa-
ted with infectious endocarditis, as well as medical-legal 
considerations, justify the generalized recommendation 
to provide antibiotic prophylaxis. Authors such as Car-
mona et al. (19) and Poveda et al. (13) agree that at least 
from the medical-legal perspective, it is prudent to ad-
minister antibiotic prophylaxis in those patients with a 
history of infectious endocarditis or who carry prosthetic 
heart valves.
Objectives
The present study consists of a literature review of the 
oral manifestations that can be seen in patients with ar-
terial hypertension, ischemic heart disease, arrhythmias 
and heart failure, and of the dental management of such 
patients. 
tion and of the same intensity as in myocardial infarc-
tion, though of shorter duration (1-3 minutes). The pain 
moreover subsides with rest and/or the administration 
of sublingual nitroglycerin. In turn, unstable or resting 
angina (since it typically manifests under resting con-
ditions) is characterized by more intense pain with a 
duration of no more than 20-30 minutes, and a poorer 
response to nitrates. This presentation can soon evolve 
towards myocardial infarction. Patients with a history 
of chest pain receive treatment in the form of antipla-
telet drugs, nitrates and calcium antagonists (6, 7). On 
the other hand, so-called Prinzmetal angina (or variant 
angina) manifests at rest and is related to coronary artery 
spasms (6, 9). 
ARRHYTHMIAS
Arrhythmias are variations in normal heart rate due to 
cardiac rhythm, frequency or contraction disorders (2). 
Atrial fibrillation is the most common type of cardiac 
arrhythmia (10), with a prevalence in the general popu-
lation of 0.4%, though this percentage increases to 3.8% 
at 60 years of age and reaches 9% in individuals over 80 
years of age (11). The frequency of electric pulse gen-
eration in the sinus node ranges from 60-80 beats per 
minute (bpm) under resting conditions and can increase 
to 200 bpm during physical exercise. Arrhythmias are 
generated when electric pulse generation proves defec-
tive. 
HEART FAILURE
Heart failure (HF) is defined as the incapacity of the 
heart to function properly, pumping insufficient blood 
towards the tissues and leading to fluid accumulation 
within the lungs, liver and peripheral tissues. In Spain, 
heart failure causes about 19,000 deaths each year. The 
survival of the affected patients is limited, due to the ag-
gravating factors and concomitant pathologies they typi-
cally present (7). Heart failure in turn is the end stage of 
other diseases such as ischemic heart disease or arterial 
hypertension.
Acute heart failure is triggered by cardiotoxic drugs or 
coronary occlusion episodes. The most common causes 
are severe and prolonged arterial hypertension, valve 
disease, ischemic heart disease and serious pericardial 
diseases. Acute heart failure typically manifests as acute 
lung edema (7). Chronic heart failure in turn is associa-
ted to antecedents of arterial hypertension and ischemic 
heart disease. Other causes are dilated myocardiopathy, 
valve disease, alcohol-induced heart disease, cor pulmo-
nale and hypertrophic and restrictive myocardiopathy. 
Diabetes mellitus in turn leads to a 2.5- to 5-fold increa-
se in the risk of developing chronic heart failure. 
The management of these patients includes identifica-
tion and correction of the causal factors (e.g., arterial 
hypertension or valve disease), and changes in lifestyle 
(elimination of toxic habits or modifications in diet). 
Drug treatment in the form of ACEIs (captopril, enala-
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Material and methods
A Medline-PubMed search was conducted of the lite-
rature over the last 10 years using the MeSH validated 
keywords: “cardiopathy”, “dental management”, “endo-
carditis”, “hypertension” and “arrhythmia”. The search 
was limited to articles in English or Spanish, and pu-
blished in the last 10 years. A total of 31 articles were 
reviewed, of which 22 were literature reviews, three 
were expert committee guides, four clinical trials and 
two case series.
Results
ARTERIAL HYPERTENSION 
1. Oral manifestations
Antihypertensive drugs are able to induce a series of ad-
verse effects with the oral cavity, as can be seen in table 
2 (3). In such situations, patients can present oral ma-
nifestations in the form of xerostomia, lichenoid reac-
tions, burning mouth sensation, loss of taste sensation or 
gingival hyperplasia, as well as extraoral manifestations 
such as sialadenosis.
2. Dental management
A well controlled hypertensive patients does not pose a 
risk in clinical practice. Consultation with the supervi-
sing physician is advisable in order to know the degree 
of hypertension control and the medication prescribed at 
that time. The patient is to be instructed to take his or her 
medication as usual on the day of dental treatment. Prior 
to such treatment, the patient blood pressure should be 
recorded, and if the values are found to be high, the visit 
should be postponed until adequate pressure control is 
achieved (4). It is preferable for the visits to be brief 
and in the morning. The prescription of anxiolytic agents 
may prove necessary in particularly anxious patients 
(5-10 mg of diazepam the night before and 1-2 hours be-
fore the appointment) before dental treatment, or alter-
natively sedation with nitrous oxide may be considered. 
A good local anesthetic technique should be performed, 
avoiding intravascular injection and using a maximum 
of two anesthetic carpules with vasoconstrictor. If more 
anesthesia is needed, it should be provided without va-
soconstrictor. Absorbable suture are to be avoided with 
adrenalin (3). During treatment, sudden changes in body 
position should be avoided, as they can cause orthosta-
tic hypotension as a side effect of the blood pressure-
lowering drugs. 
When the patient does not present good blood pressure 
control, it is best to refer him or her to the physician in 
order to ensure adequate control before dental treatment. 
In the case of emergency dental visits, treatment should 
be conservative, with the use of analgesics and antibio-
tics. Surgery is to be avoided until adequate blood pres-
sure control has been secured.
Certain nonsteroidal antiinflammatory drugs (NSAIDs), 
such as ibuprofen, indomethacin or the naproxen, can 
interact with antihypertensive drugs (beta-blockers, diu-
retics, ACEIs) (20), thereby lowering their antihyperten-
sive action. Normally more than five days of treatment 
with both types of drugs are required for interactions to 
manifest (20, 21); as a result, NSAIDs should not be pre-
scribed for longer than this five-day period.
- Local anesthesia with vasoconstrictor
The existing controversy over the use of local anesthe-
sia with a vasoconstrictor is explained by the possible 
ANTIHYPERTENSIVE DRUGS GENERIC NAME TRADE NAME SIDE EFFECTS
DIURETICS
Thiazides, furosemide, 
ethacrinic acid, spiro-
nolactone
Esidrex®, Hidrosa-
luretil®, Seguril®, 
Salidur®, Aldac-
tone®
Xerostomia, 
nauseas
ADRENERgIC BloCkINg 
AGENTS
Clonidine, methyldopa, 
propanolol, rauwolfia 
alkaloids
Catapresan®, Aldo-
met®
Xerostomia, de-
pression, sedation, 
sialadenosis
Methyldopa, propa-
nolol,
Aldomet®, Su-
mial® lichenoid reaction
ANgIoTENSIN-CoNVERTINg 
ENzyME INHIBIToRS (ACEIs)
Captopril, enalapril Capoten®, Tenso-prel®, Renitec®
lichenoid reac-
tion, burning 
mouth, loss of 
taste
CAlCIUM ANTAgoNISTS
Nifedipine, amlodipine, 
verapamil , diltiazem
Adalat®, Cordi-
lán®, Norvasc®, 
Astudal®, Amlor®, 
Veratensin®
Gingival hyperpla-
sia, xerostomia
oTHERS VASoDIlAToRS
Hydralazine, nitroprus-
side,  minoxidil
Hydraprés®, loni-
tén®
Cephalgia, nau-
seas
Table 2. Oral adverse effects of antihypertensive treatment.
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adverse effects of these substances upon blood pressure 
and/or heart rate (22). However, different studies have 
shown that no significant increases in arterial pressure 
are induced by the use of anesthesia with a vasocons-
trictor in dental treatments. Silvestre et al. (23) observed 
no significant changes in systolic blood pressure before, 
during or after dental extractions – the lowest pressures 
being recorded at the end of the procedure, and the hig-
hest at the time of extraction. In a recent publication, 
laragnoit et al. (24), in coincidence with other studies in 
patients with heart diseases, reported that the administra-
tion of 2% lidocaine with epinephrine (1: 100,000) indu-
ces no significant changes in the hemodynamic parame-
ters during dental treatment – this suggesting that its use 
is safe in minor dental operations, provided a good anes-
thetic technique is performed and the treatment prescri-
bed by the cardiologist is maintained (25). Patients with 
cardiovascular disease are at a greater risk of massive 
endogenous adrenalin release secondary to deficient lo-
cal anesthesia than of reaction to the small amount of 
vasoconstrictor used in local anesthetics (9). In effect, 
pain is responsible for endogenous catecholamine relea-
se, and this in turn can give rise to hemodynamic altera-
tions. Pain control is essential during dental procedures, 
and epinephrine affords excellent bleeding control in the 
context of local anesthesia (24). Nevertheless, vasocons-
trictor use should be limited, taking care not to exceed 
0.04 mg of adrenaline (2 carpules containing 1.8 ml of 
anesthetic with adrenalin 1: 100,000) (7).
- Hypertensive emergencies
In the case of a hypertensive emergency (>120/210 
mmHg), the emergency service should be activated by 
dialing 112, and furosemide should be administered (40 
mg, via the oral route). If this proves insufficient to res-
tore pressure control, captopril should be administered 
(25 mg via the oral or sublingual route). If the blood 
pressure fails to decrease within 30 minutes after these 
measures, the patient should be referred to the nearest 
Hospital Emergency Department.
ISCHEMIC HEART DISEASE
1. Oral manifestations
If the patient is receiving anticoagulant or antiplatelet 
treatment, bleeding may occur, manifesting as hemato-
mas, petechiae or gingival bleeding.
2. Dental management
A patient who has suffered acute myocardial infarction 
is at a high risk of suffering another infarction episo-
de or severe arrhythmias. It has been reported that over 
70% of all recurrences take place in the first month after 
the initial vascular event (26). In dental practice a mi-
nimum safety period of 6 months has been established 
before any oral surgical procedure can be carried out. 
However, studies in recent years have underscored the 
need to revise these criteria. At present, the evaluation 
of exercise testing in the first 6 days after infarction is 
considered essential for risk assessment and prognosis. 
If such testing is well tolerated by the patient, the risk is 
taken to be low. No ideal minimum time has been esta-
blished, though many authors consider 4-6 weeks after 
infarction to be a prudent period (6). In this time, dental 
treatment should be limited to emergency procedures 
aimed at affording pain relief: extractions, the draina-
ge of abscesses and pulpectomies, preferably carried 
out in the hospital setting. After this safety period, the 
treatment decision should be established on the basis of 
the situation and medical condition of each individual 
patient (7, 9).
Consultation with the supervising physician is advised 
(26) in order to know the type of heart disease (angi-
na or infarction), its severity, the time elapsed from the 
cardiological event, the clinical complications, and the 
treatment received by the patient. In turn, the patient 
should continue taking the prescribed medication as 
usual. If nitrates are used, the patient should bring them 
to each visit to the dental clinic (8), in case chest pain 
develops. Authors such as Silvestre et al. (6) mention 
the possibility of administering nitrite as a preventive 
measure before local anesthesia (27). In the case of 
very anxious patients, premedication can be administe-
red to lessen anxiety and stress (5-10 mg of diazepam 
the night before and 1-2 hours before treatment). Some 
authors use inhalatory sedation in the form of nitrous 
oxide / oxygen (8). The visits should be brief (less than 
30 minutes) and should be programmed for during the 
day – avoiding the early morning hours, which is when 
heart attacks are most frequent, as well as the late af-
ternoon hours, when tiredness and stress are greater 
(6). As has been commented above, a good anesthetic 
technique is required, taking care not to inject the solu-
tion into a blood vessel, and using a maximum of two 
carpules with vasoconstrictor. In turn, if anesthetic re-
inforcement is needed, it should be provided without a 
vasoconstrictor (28). The patient should be placed in the 
position most comfortable for him or her (semi-supine), 
and should get up carefully in order to avoid orthostatic 
hypotension. Depending on the patient, blood pressure 
and pulsioxymetric monitoring may be required before 
and during dental treatment (26). If the patient is recei-
ving anticoagulants, the international normalized ratio 
(INR) on the day of treatment should be determined, and 
treatment should be provided within the recommended 
limits (< 3.5), with local hemostasis if surgery is planned 
(26, 28). If the patient is receiving antiplatelet medica-
tion, excessive local bleeding is to be controlled. The 
local hemostatic measures that can be used comprise 
bone wax, sutures, gelatin of animal origin (gelfoam®), 
regenerated oxidized cellulose (Surgicel®), collagen, 
platelet rich plasma, thrombin (Thrombostat®), fibrin 
sealants (Tissucol®), electric or laser scalpels, antifibri-
nolytic agents such as tranexamic acid (Amchafibrin®) 
e102
J Clin Exp Dent. 2011;3(2):e97-105.                                                                Management of cardiological patients.
or epsilon-aminocaproic acid (Caproamin®) (3). Table 3 
summarizes the management of these patients.
If the patient develops chest pain during dental treatment, 
the procedure should be suspended immediately, and a 
sublingual nitrite tablet should be administered (0.4-0.8 
mg), together with nasal oxygen (3 liters/minute). If the 
pain subsequently subsides, continuation of treatment 
can be considered, or alternatively an appointment can 
be made for some other day. If the pain fails to subside 
after 5 minutes, a second sublingual tablet should be ad-
ministered. If the pain fails to disappear 15 minutes af-
ter onset, acute myocardial infarction is to be suspected, 
and the patient must be transferred to a hospital center 
(7, 9), as shown in figure 1. 
ARRHYTHMIAS
1. Oral manifestations
Many antiarrhythmic drugs have side effects such as 
gingival hyperplasia or xerostomia. 
2. Dental management
Consultation with the supervising physician is advised 
in order to know the current condition of the patient and 
the type of arrhythmia involved, as well as the medica-
tion prescribed (10). It must be checked that the patient 
uses the medication correctly. Anxiolytics can be used to 
lessen stress and anxiety (10, 11). Short visits in the mor-
ning are to be preferred. Patient monitoring, with recor-
ding of the pulse, is indicated before starting treatment. 
It is very important to limit the use of a vasoconstrictor in 
local anesthesia, with the administration of no more than 
two carpules. The treatment planned should not be too 
long or complicated. According to Becker (29), although 
modern pacemakers are more resistant to electromagne-
tic interferences, caution is required when using electri-
cal devices (e.g., ultrasound and electric scalpels) that 
might interfere with pacemakers – particularly the ol-
der models, since most such devices developed in the 
last 30 years are bipolar and are generally not affected 
by the small electromagnetic fields generated by dental 
equipment. It is therefore important to know the type of 
pacemaker, the degree of electromagnetic protection of 
the generator, and the nature of the arrhythmia (9). Pa-
cemakers and automatic defibrillators pose a low risk of 
infectious endocarditis, and do not need antibiotic cove-
rage before dental treatment (9).
If important arrhythmia develops during dental treatment, 
the procedure should be suspended, oxygen is to be pro-
vided, and the patient vital signs are to be assessed: body 
temperature (normal values: 35.5-37ºC), pulse (normal 
values: 60-100 bpm), respiratory frequency (normal va-
lues in adults: 14-20 cycles or respirations per minute), 
blood pressure (normal values: systolic blood pressure 
under 140 mmHg and diastolic blood pressure under 90 
mmHg). Sublingual nitrites are to be administered in the 
event of chest pain. The patient should be placed in the 
Trendelenburg position, with vagal maneuvering where 
necessary (Valsalva maneuver, massage in the carotid 
pulse region, etc.). The dental team should be prepared 
for basic cardiopulmonary resuscitation and initiation 
of the emergency procedure for evacuation to a hospital 
center, if necessary.
DENTAL MANAGEMENT IN PATIENTS wITH ISCHEMIC HEART DISEASE 
- Consultation → type of heart disease, severity, time elapsed from the cardiological event, clinical compli-
cations, treatment received.
· Take the prescribed medication as usual 
· If nitrates are used, the patient should bring them 
- Take as a preventive measure before local anesthesia 
             - Take in case chest pain develops
· Anticoagulated patient → determine INR on the day of treatment 
· Antiplatelet patient → local hemostatic measures
- Before 4-6 weeks after infarction → only emergency procedures
- Very anxious patients → premedication (5-10 mg of diazepam the night before and 1-2 hours before treat-
ment)
- Brief visits (less than 30 minutes) → avoiding early morning hours and late afternoon hours
- Anesthesia → not to inject into a blood vessel
         → a maximum of two carpules with vc
   · If anesthetic reinforcement is needed: anesthesia without vc 
- Patient in semi-supine position
- Patient should get up carefully → to avoid orthostatic hypotension 
- Monitoring may be required: blood pressure and pulsioxymetric 
vc: vasoconstrictor 
If surgery 
is needed
Table 3. Summary of dental management in patients with ischemic heart disease.
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HEART FAILURE
1. Oral manifestations
Due to the drug treatments used by patients with heart 
failure, a series of oral manifestations can be observed. 
In this context, ACEIs (captopril, enalapril) can produce 
lichenoid reactions, burning mouth sensation and a loss 
of taste sensation, while diuretics (furosemide) can pro-
duce xerostomia.
2. Dental management
Consultation with the supervising physician is advised 
in order to know the current condition of the patient and 
the medication prescribed. The patient should be recei-
ving medical care, and heart failure should be compen-
sated. Dental treatment is to be limited to patients who 
are in stable condition, since these individuals are at an 
important risk of developing serious arrhythmias and 
even sudden death secondary to cardiopulmonary arrest. 
In patients with heart failure, including those presenting 
palpitations, asthenia or dyspnea, it is important to only 
provide emergency care, and to do so in the hospital set-
ting. Anxiety and stress are to be avoided during the vi-
sits, which in turn should be brief (less than 30 minutes) 
and are to be programmed for the morning hours. The 
patient should be placed in the semi-supine position in 
a chair, with control of body movements (which should 
be slow), in order to avoid orthostatic hypotension. In 
patients administered digitalis agents (digoxin, methyl-
digoxin), the vasoconstrictor dose is to be limited to two 
anesthetic carpules, since this drug combination can fa-
vor the appearance of arrhythmias. Aspirin (acetylsali-
cylic acid) can lead to sodium and fluid retention, and 
therefore should not be prescribed in patients with heart 
failure.
In the event of an emergency (i.e., lung edema), and after 
contacting the emergency service, the patient should be 
placed seated with the legs lowered, and receiving nasal 
oxygen at a rate of 4-6 liters/minute. Sublingual nitro-
glycerin tablets are indicated (0.4-0.8 mg), and the dose 
AMI: acute myocardial infarction
Figure 1. Management of patients with ischemic heart disease in the event of chest pain during dental treatment.
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may be repeated every 5 or 10 minutes if blood pressure 
is maintained (7). Acute lung edema manifests as sudden 
onset or progressive dyspnea, cough with expectoration, 
cyanosis, skin coldness, intense perspiration and critica-
lly ill sensation. The patient typically refers suffocation 
and laryngeal irritation, and the condition may simulate 
an asthma attack.
PREVENTION OF ENDOCARDITIS
The most widely accepted endocarditis prevention proto-
cols are those of the American Heart Association (AHA) 
and the British Society of Antimicrobial Chemotherapy 
(BSAC). The difference between the two protocols cen-
ters on the amount of amoxicillin to be administered (2 
and 3 grams according to the AHA and BSAC, respec-
tively) (12). The present study focuses on the protocol 
of the AHA (Table 4), which was modified in 2007 with 
the purpose of further clarifying when prophylaxis for 
infectious endocarditis is recommendable or not, and of 
offering more uniform and coherent global recommen-
dations.
Infectious endocarditis is not an emergency condition in 
the dental clinic, though its associated mortality is high. 
The disease is to be suspected when the patient presents 
unexplained fever for over one week together with heart 
murmurs. The symptoms are fever, chills, nocturnal 
perspiration, a generally worsened condition, lessened 
appetite, fatigue, weakness and discomfort, and tend to 
manifest 10-15 days after the causal or triggering event 
or intervention. Symptoms of heart failure may also be 
seen. The typical clinical sign is the appearance of pete-
chiae with a clear center on the skin of the flexure zones 
of the extremities, supraclavicular region, conjunctival 
mucosa of the lower eyelids, and hard palate.
According to the AHA (30), antibiotic prophylaxis for 
dental procedures is only indicated in patients with heart 
disorders related to a very high risk of developing en-
docarditis:
Prosthetic heart valves.- 
Previous infectious endocarditis.- 
Congenital heart disease, only in the following - 
situations:
Untreated cyanotic congenital heart o 
disease, including shunts and ducts.
Congenital heart defects fully repaired o 
with material or prostheses placed 
through surgery or with catheters, dur-
ing the first 6 months after the opera-
tion.
Repaired congenital heart disease, o 
though with residual defects associ-
ated to prosthetic materials.
Heart transplant patients who develop cardiac - 
valve disease.
Prophylaxis is recommended in all dental procedures in-
volving the manipulation of gingival tissue, the periapi-
cal region of the teeth, or perforations of the oral muco-
sa, such as extractions, endodontic treatment surpassing 
the periapical limits, the placement of retraction sutures, 
biopsies, suture removal, the placement of brackets, or 
buccal cleaning operations, among other.
Prophylaxis in turn is not recommended in the routine 
injection of anesthetic solutions in non-infected tissues, 
dental X-rays, the placement of removable dentures or 
orthodontic devices, loss of temporal teeth, or bleeding 
SITUATIoN AGENT
SINglE DoSE 30-60 min BEFoRE PRoCEDURE 
ADUlTS CHIlDREN 
Standard general prophylaxis 
(oral) Amoxicillin 2gr
50 mg/kg
(maximum 2 gr)
Unable to take oral medica-
tion 
Ampicillin
Cefazolin or Ce-
ftriaxone 
2 gr im or iv
1gr im or iv
50 mg/kg im or iv
50 mg/kg im or iv
Allergic to 
penicillins 
Oral
Cephalexin *
C l i n d a m y c i n 
Azithromycin or 
Clarithromycin
2gr
600 mg
500 mg
50 mg/kg
20 mg/kg
15 mg/kg
Unable to take 
oral medication
Cefazolin or Ce-
ftriaxone 
Clindamycin
1g im or iv
600 mg im or iv
50 mg/kg im or iv
20 mg/kg
im: intramuscular; iv: intravenous
* Another first or second generation cephalosporin can be used via the oral route, at equivalent doses. Cephalosporins should 
not be used in patients with a history of anaphylaxis, angioedema or urticaria in response to penicillins or ampicillin.
Table 4. Prophylactic antibiotic protocol for infectious endocarditis, recommended by the American Heart Association (AHA).
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secondary to lip or oral mucosa traumatisms (30).
- Recommendations
Although not based on scientific evidence, the American 
College of Cardiology recommends that “individuals at 
risk of developing bacterial endocarditis should observe 
the best hygiene possible”. other authors consider that 
maintaining good oral health is probably more important 
for the prevention of endocarditis than the prophylactic 
administration of antibiotics before certain dental ope-
rations (31).
It has been seen that bacteremia may develop after trau-
matic ulcer formation associated with removable dentu-
res. Periodic controls are thus advised to prevent them 
from developing (12).
Some investigators such as Blanco in 2004 consider that 
it is advisable to perform rinses with 0.12% chlorhexi-
dine for at least 30 seconds, before any dental treatment, 
since this produces an important reduction in bacteremia 
of oral origin (12, 15).
If the patient has failed to correctly follow the pro-
phylactic treatment regimen, antibiotics are to be admi-
nistered as soon as possible, since this has been shown to 
be effective when carried out in the two hours following 
the development of bacteremia (12). 
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